


IN THE CLAIMS:

Please replace the present claim set with the following. Specifically, please amend claim 7 and cancel claims 78, 79, 84-91 and 98-103 as follows:

1 (original). A compound of Formula I:



Formula I

a pharmaceutically acceptable salt or stereoisomer thereof,
wherein

A is C_{2-3} alkylene- $N(R_1)(R_2)$ or 1-(phenylmethyl)-pyrrolidin-3-yl;

R_1 is $(CH_2)_n Q$, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamanyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and

Q is optionally substituted with one or two moieties independently selected from halo,

C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2;

R_2 is H or C_{1-6} alkyl; or

R_1 and R_2 , together with the nitrogen atom to which R_1 and R_2 are attached, form 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 1,4-dioxa-8-azido-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H- β -carbolinyl, or 8-aza-bicyclo[3.2.1]octanyl, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, $C(O)phenyl$, OH, CN, O-phenyl or $(CH_2)_m Z$,

Z is benzisoxazolyl, indazolyl, benzothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

-2-

USHMR2021US PCT

Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, trifluoromethyl, S(O)₂NH₂, or cyano, and

m is 0 or 1.

2. (original) A compound according to claim 1 wherein R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form piperazinyl.
3. (original) The compound according to claim 2 which is 3-{3-[3-(4-pyrimidin-2-yl-piperazin-1-yl)-propoxy]-phenyl}-thieno[2,3-*d*]isoxazole.
4. (original) The compound according to claim 2 which is 3-{3-[3-(4-phenyl-piperazin-1-yl)-propoxy]-phenyl}-thieno[2,3-*d*]isoxazole.
5. (original) The compound according to claim 2 which is 3-(3-[3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propoxy]-phenyl)-thieno[2,3-*d*]isoxazole.
6. (original) The compound according to claim 2 which is 3-(3-[3-[4-(2-fluoro-phenyl)-piperazin-1-yl]-propoxy]-phenyl)-thieno[2,3-*d*]isoxazole.
7. (currently amended) The compound according to claim 2 which is 3-{3-[2-(4-phenyl-piperazin-1-yl)-ethoxy]-phenyl}-thieno[2,3-*d*]isoxazole.
8. (original) A compound according to claim 1 wherein R₁ is indanyl.
9. (original) The compound according to claim 8 which is indan-2-yl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
10. (original) The compound according to claim 8 which is indan-1-yl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
11. (original) The compound according to claim 8 which is indan-1-yl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
12. (original) The compound according to claim 8 which is indan-2-yl-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
13. (original) A compound according to claim 1, wherein R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form 1,2,3,4-tetrahydroisoquinolinyl.
14. (original) The compound according to claim 13 which is 2-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-1,2,3,4-tetrahydro-isoquinoline.
15. (original) The compound according to claim 13 which is 2-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-1,2,3,4-tetrahydro-isoquinoline.
16. (original) A compound according to claim 1 wherein R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form azepanyl.

17. (original) The compound according to claim 16 which is 3-[3-(2-azepan-1-yl-ethoxy)-phenyl]-thieno[2,3-*d*]isoxazole.
18. (original) A compound according to claim 1 wherein R₁ is adamantyl.
19. (original) The compound according to claim 18 which is adamantan-1-yl-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
20. (original) The compound according to claim 18 which is adamantan-1-yl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
21. (original) A compound according to claim 1 wherein Q is thiaryl, phenyl, or pyridyl; or R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form morpholinyl, piperidinyl, pyrrolidinyl, or azocanyl.
22. (original) The compound according to claim 21 which is 1-phenyl-2-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propylamino]-ethanol.
23. (original) The compound according to claim 21 which is 4-{2-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propylamino]-ethyl}-benzenesulfonamide.
24. (original) A compound according to claim 1 wherein A is C₂₋₃alkylene-N(R₁)(R₂); R₁ is (CH₂)_nQ; n is 1; R₂ is H; Q is thiaryl, phenyl, or pyridyl; or R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form morpholinyl, piperidinyl, pyrrolidinyl, or azocanyl.
25. (original) The compound according to claim 24 wherein Q is thiaryl.
26. (original) The compound of claim 25 which is [3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-thiophen-2-ylmethyl-amine.
27. (original) The compound of claim 25 which is [2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-thiophen-2-ylmethyl-amine.
28. (original) The compound of claim 25 which is [2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-thiophen-3-ylmethyl-amine.
29. (original) The compound of claim 25 which is [3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-thiophen-3-ylmethyl-amine
30. (original) A compound according to claim 24 wherein Q is phenyl.
31. (original) The compound according to claim 30 which is benzyl-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

32. (original) The compound of claim 30 which is benzyl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
33. (original) The compound of claim 30 which is (2-methoxy-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
34. (original) The compound of claim 30 which is (3-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
35. (original) The compound of claim 30 which is (2,6-difluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
36. (original) The compound of claim 30 which is (2,6-difluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
37. (original) The compound of claim 30 which is (2-fluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
38. (original) The compound of claim 30 which is (4-fluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
39. (original) The compound of claim 30 which is (4-chloro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
40. (original) The compound of claim 30 which is (4-methoxy-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
41. (original) The compound of claim 30 which is 4-{[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propylamino]-methyl}-benzenesulfonamide.
42. (original) The compound of claim 30 which is (4-chloro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
43. (original) The compound of claim 30 which is (4-methyl-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
44. (original) The compound of claim 30 which is (3,4-dichloro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
45. (original) The compound of claim 30 which is (2,4-difluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
46. (original) The compound of claim 30 which is [2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]- (4-trifluoromethyl-benzyl)-amine.
47. (original) The compound of claim 30 which is (2-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
48. (original) The compound of claim 30 which is 2-chloro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
49. (original) The compound of claim 30 which is (3-methoxy-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

50. (original) The compound of claim 30 which is (3,4-difluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
51. (original) The compound of claim 30 which is (4-methyl-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
52. (original) The compound of claim 30 which is (2-chloro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
53. (original) The compound of claim 30 which is (3-methoxy-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
54. (original) The compound of claim 30 which is (3,4-difluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
55. (original) The compound of claim 30 which is (2,4-difluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
56. (original) The compound of claim 30 which is [3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-[2-(trifluoromethyl-benzyl)-amine.
57. (original) The compound of claim 30 which is [3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-[4-(trifluoromethyl-benzyl)-amine.
58. (original) The compound of claim 30 which is (4-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
59. (original) The compound of claim 30 which is [2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-[2-(trifluoromethyl-benzyl)-amine.
60. (original) The compound of claim 30 which is benzyl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
61. (original) A compound according to claim 24 wherein Q is pyridyl.
62. (original) The compound of claim 61 which is pyridin-3-ylmethyl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
63. (original) The compound of claim 61 which is pyridin-3-ylmethyl-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
64. (original) A compound according to claim 24 wherein R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form piperidinyl.
65. (original) The compound according to claim 64 which is 3-[3-(3-piperidin-1-yl-propoxy)-phenyl]-thieno[2,3-*d*]isoxazole.
66. (original) The compound of claim 64 which is 3-[3-[2-(4-phenyl-piperidin-1-yl)-ethoxy]-phenyl]-thieno[2,3-*d*]isoxazole.
67. (original) The compound of claim 64 which is 3-[3-(2-piperidin-1-yl-ethoxy)-phenyl]-thieno[2,3-*d*]isoxazole.


68. (original) The compound of claim 64 which is 3-[3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl]-thieno[2,3-*d*]isoxazole.
69. (original) The compound of claim 64 which is 3-[3-[2-(4-propyl-piperidin-1-yl)-ethoxy]-phenyl]-thieno[2,3-*d*]isoxazole.
70. (original) A compound according to claim 24 wherein R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form pyrrolidinyl.
71. (original) The compound of claim 70 which is 3-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-thieno[2,3-*d*]isoxazole.
72. (original) A compound according to claim 24 wherein R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form azocanyl.
73. (original) The compound of claim 72 which is 3-[3-(2-azocan-1-yl-ethoxy)-phenyl]-thieno[2,3-*d*]isoxazole.
74. (original) A compound according to claim 24 wherein R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form morpholinyl.
75. (original) A compound according to claim 1 wherein A is 1-(phenylmethyl)-pyrrolidin-3-yl.
76. (original) The compound of claim 75 which is (S)-(+)-3-[3-(1-benzyl-pyrrolidin-3-yloxy)-phenyl]-thieno[2,3-*d*]isoxazole.
77. (original) The compound according to claim 75 which is (R)-(-)-3-[3-(1-benzyl-pyrrolidin-3-yloxy)-phenyl]-thieno[2,3-*d*]isoxazole.
78. (canceled) A method for antagonizing the effects of dopamine at the D₄ receptor comprising administering a compound according to claim 1 to a patient in need thereof.
79. (canceled) The method as defined in claim 78 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
80. (original) A composition comprising a compound according to claim 1 in admixture with an inert carrier.
81. (original) The composition according to claim 80 wherein said inert carrier is a pharmaceutical carrier.
82. (original) A method of treating psychoses comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
83. (original) The method as defined in claim 82 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
84. (canceled) A method of treating Attention Deficit Hyperactivity Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
85. (canceled) The method as defined in claim 84 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

86. (canceled) A method of treating Obsessive-Compulsive Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
87. (canceled) The method as defined in claim 86 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.
88. (canceled) A method of treating Substance Abuse comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
89. (canceled) The method as defined in claim 88 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.
90. (canceled) A method of treating Substance Dependence comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
91. (canceled) The method as defined in claim 90 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.
92. (original) A method of treating Parkinson's Disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
93. (original) The method as defined in claim 92 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.
94. (original) A method of treating Parkinsonism comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
95. (original) The method as defined in claim 94 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.
96. (original) A method of treating Tardive Dyskinesia comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
97. (original) The method as defined in claim 96 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.
98. (canceled) A method of treating Gilles de la Tourette Syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
99. (canceled) The method as defined in claim 98 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.
100. (canceled) A method of treating Conduct Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
101. (canceled) The method as defined in claim 100 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

102. (canceled) A method of treating Oppositional Defiant Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

103. (canceled) The method as defined in claim 102 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

104. (original) A method of making a compound of Formula I:



I

a pharmaceutically acceptable salt or stereoisomer thereof,
wherein

A is C₂₋₃ alkylene-N(R₁)(R₂);

R₁ is (CH₂)_nQ, CH₂CH(OH)Q, CH(CH₃)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantlyl, wherein

Q is thieryl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxophenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and
Q is optionally substituted with one or two moieties independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, S(O)₂NH₂, trifluoromethyl, or cyano, and
n is 1 or 2;

R₂ is H or C₁₋₆ alkyl; or


R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H-β-carbolinyl, or 8-aza-bicyclo[3.2.1.]octanyl, each of which may be mono- or independently di-substituted with halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C(O)phenyl, OH, CN, O-phenyl or (CH₂)_mZ,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxophenyl, or phenyl, and

Z, $\text{CH}(\text{OH})\text{phenyl}$ or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $\text{S}(\text{O})_2\text{NH}_2$, or cyano, and

m is 0 or 1;

comprising the step coupling a reagent of formula II




wherein

X is Br, Cl or I; and

p is 2 or 3;


with a reagent of formula III



III

wherein R_1 and R_2 are defined as in formula I;
to provide a compound of formula I.

105. (original) A method of making a compound of Formula I:




a pharmaceutically acceptable salt or stereoisomer thereof,

wherein


A is 1-(phenylmethyl)-pyrrolidin-3-yl;

comprising the step of coupling a reagent of formula II



II


with a reagent of formula III



III

to provide the compound of formula I.

106. (original) A method of making a compound of Formula I:



I

a pharmaceutically acceptable salt or stereoisomer thereof,
wherein

A is C₂₋₃ alkylene-N(R₁)(R₂);

R₁ is (CH₂)_n Q, CH₂CH(OH)Q, CH(CH₃)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl,
wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and

Q is optionally substituted with one or two moieties independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, S(O)₂NH₂, trifluoromethyl, or cyano, and n is 1 or 2;

R₂ is H or C₁₋₆ alkyl; or


R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form 4,5,6,7-tetrahydrothieno [3,2-c] pyridinyl, 1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H-β-carbolinyl, or 8-aza-bicyclo[3.2.1.]octanyl, each of which may be mono- or independently di-substituted with halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C(O)phenyl, OH, CN, O-phenyl or (CH₂)_mZ,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, trifluoromethyl, S(O)₂NH₂, or cyano, and


m is 0 or 1;

comprising the step of coupling a reagent of formula II



II

with a reagent of formula III




III

wherein

 R_1 , and R_2 are defined as in formula I; p is 2 or 3; and Y is Br, Cl, I, aryl sulfonate or alkyl sulfonate;

to provide the compound of formula I.

107. (original) A method of making a compound of Formula I:



I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

 A is C_{2-3} alkylene- $\text{N}(\text{R}_1)(\text{R}_2)$; R_1 is $(\text{CH}_2)_n \text{Q}$, $\text{CH}_2\text{CH}(\text{OH})\text{Q}$, $\text{CH}(\text{CH}_3)\text{Q}$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl,

wherein

 Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $\text{S}(\text{O})_2\text{NH}_2$, trifluoromethyl, or cyano, and n is 1 or 2;

R_2 is H or C_{1-6} alkyl; or


R_1 and R_2 , together with the nitrogen atom to which R_1 and R_2 are attached, form 4,5,6,7-tetrahydrothieno[3,2-c] pyridinyl, 1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H- β -carbolinyl, or 8-aza-bicyclo[3.2.1]octanyl, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, $C(O)phenyl$, OH, CN, O-phenyl or $(CH_2)_mZ$,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

Z , $CH(OH)phenyl$ or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and

m is 0 or 1;

comprising the step of reducing a compound of the formula




wherein p is 1 or 2; and

R_1 and R_2 are as defined in formula I;

to provide a compound of formula I.

108. (original) A compound of formula



wherein

p is 1 or 2; and

R₁ is (CH₂)_nQ, CH₂CH(OH)Q, CH(CH₃)Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and

Q is optionally substituted with one or two moieties independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, S(O)₂NH₂, trifluoromethyl, or cyano, and

n is 1 or 2;

R₂ is H or C₁₋₆ alkyl; or


R₁ and R₂, together with the nitrogen atom to which R₁ and R₂ are attached, form 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 1,4-dioxa-8-azido-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H-β-carbolinyl, or 8-aza-bicyclo[3.2.1.]octanyl, each of which may be mono- or independently di-substituted with halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C(O)phenyl, OH, CN, O-phenyl or (CH₂)_mZ,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, trifluoromethyl, S(O)₂NH₂, or cyano, and

m is 0 or 1.

109. (original) A compound of formula



wherein X is Br, Cl or I; and
p is 2 or 3.